> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Danaher Lifts 2026 Adjusted EPS Outlook To $8.57-$8.62 As Core Growth Ex-Respiratory Hits 5.5%
- URL: https://www.bullished.co/danaher-lifts-2026-adjusted-eps-outlook-to-8-57-8-62-as-core-growth-ex-respiratory-hits-5-baa72797/
- Published: 2026-10-21T10:05:54.000Z
- Updated: 2026-10-28T19:22:47.000Z
- Description: Third-quarter net earnings rose 34.5% to $1.2 billion, helped by a $263 million net discrete tax benefit.
- Author: Matteo Parrino
- Tags: Earnings, DHR, Industry: Healthcare

[Danaher](https://www.bullished.co/tag/dhr/) raised its 2026 adjusted earnings-per-share guidance to [$8.57 to $8.62](https://www.sec.gov/Archives/edgar/data/0000313616/000031361626000201/dhr-20261021xex991.htm?ref=bullished.co), from $8.45 to $8.60, in its third-quarter earnings release, furnished with an [8-K](https://www.sec.gov/Archives/edgar/data/0000313616/000031361626000201/dhr-20261021.htm?ref=bullished.co) that EDGAR accepted Tuesday evening. The release itself is dated October 21.

## What the quarter showed

Net earnings were $1.2 billion, or $1.71 per diluted share, up 34.5% from a year earlier. Revenue rose 8.5% to $6.6 billion.

Adjusted earnings per share grew 11.5% to $2.11\. Core revenue, which strips out currency swings and acquisitions, rose 3.0%, or 5.5% excluding respiratory testing.

Operating cash flow was $1.9 billion and free cash flow, which subtracts capital spending, was $1.6 billion.

CEO Julie Sawyer Montgomery said Danaher delivered "better-than-expected third quarter revenue, earnings and cash flow," and cited "improving trends we saw across our end markets."

## The tax item and the segments

Reported earnings got a lift from $263 million of net discrete tax benefits, tied mainly to releasing reserves for uncertain tax positions after audit settlements. The release's adjusted EPS reconciliation removes a $0.37 per-share discrete tax adjustment.

By segment, core sales grew 5.0% in Biotechnology, 4.5% in Life Sciences and 0.5% in Diagnostics. Excluding respiratory testing, Diagnostics core growth was 6.5%.

The company also began excluding tariff refunds passed to customers from core growth this quarter.

## Fourth-quarter outlook and the call

For the fourth quarter, Danaher expects core revenue excluding respiratory testing to grow 4.0% to 5.0%. It sees respiratory testing as a headwind of about 150 basis points, or 1.5 percentage points, leaving core growth of about 3.0%.

The company also guides to an adjusted operating margin of about 29.5% for the quarter. Management discusses the results and key assumptions on an investor call starting at 8:00 a.m. ET Wednesday.

The call, with its slide presentation, is where management is due to lay out the assumptions behind the raised range.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — DANAHER CORP /DE/ (DHR)](https://www.sec.gov/Archives/edgar/data/0000313616/000031361626000201/dhr-20261021.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit dhr-20261021xex991.htm — DANAHER CORP /DE/ 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0000313616/000031361626000201/dhr-20261021xex991.htm?ref=bullished.co) — SEC EDGAR

### More on Danaher

- [Danaher's New CEO Says Growth Fell Short Of Portfolio's 'Full Potential' And Names Share Gain Her 'Report Card'](https://www.bullished.co/danahers-new-ceo-says-growth-fell-short-of-portfolios-full-potential-and-names-share-gain-ab8ddb5f/)
- [Danaher's Tax Line Swung To A $75 Million Benefit As Diagnostics Margin Fell To 21.3%](https://www.bullished.co/danahers-tax-line-swung-to-a-75-million-benefit-as-diagnostics-margin-fell-to-21-3-227fe7ca/)
- [Danaher Adds Former CFO Comas And Biotech Executive Hershberg, Lifting Board To 13 Seats](https://www.bullished.co/danaher-adds-former-cfo-comas-and-biotech-executive-hershberg-lifting-board-to-13-seats-4a509fa6/)

[All Danaher (DHR) coverage →](https://www.bullished.co/tag/dhr/)